Recommendations when to order or not order the test. May include related or preferred tests.
In the absence of active lesions, this is the preferred serology test for diagnosing herpes simplex viral infection.
Mnemonic
Unique test identifier.
HERP PAN 2
Methodology
Process(es) used to perform the test.
Semi-Quantitative Chemiluminescent Immunoassay
Performed
Days of the week the test is performed.
Sun-Sat
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
1-2 days
New York DOH Approval Status
Indicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum separator tube.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimen. Mark specimens plainly as "acute" or "convalescent."
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Plasma or urine. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Remarks
Stability
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by CIA
Effective February 18, 2020
0.89 IV or less
Negative - No significant level of detectable IgG antibody to HSV type 2 glycoprotein G.
0.90-1.09 IV
Equivocal - Questionable presence of IgG antibody to HSV type 2 glycoprotein G. Repeat testing in 10-14 days may be helpful.
1.10 IV or greater
Positive - IgG antibody to HSV type 2 glycoprotein G detected, which may indicate a current or past HSV infection.
Interpretive Data
Background information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Individuals infected with HSV may not exhibit detectable IgG antibody to type-specific HSV antigens 1 and 2 in the early stages of infection. Detection of antibody presence in these cases may only be possible using a non-type specific screening test.
Compliance Category
FDA
Note
Additional information related to the test.
For CSF, refer to Herpes Simplex Virus Type 1 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (ARUP test code 0050379) and Herpes Simplex Virus Type 2 Glycoprotein G-Specific Antibody, IgG by ELISA, CSF (ARUP test code 0050359).
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Other names that describe the test. Synonyms.
HSV
HSV glycoprotein G type 1 and 2
HSV typing 1 and 2
Herpes Simplex Type 1 and Type 2 Glycoprotein G-Specific Antibodies, IgG by CIA
Chat
Feedback
